<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981966</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160596H</org_study_id>
    <nct_id>NCT02981966</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects</brief_title>
  <official_title>Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects (11038)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in
      endogenous glucose production (EGP) following the induction of glucosuria (when glucose is
      excreted in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Researchers will measure the rate of hepatic and renal glucose production following
      dapagliflozin administration to determine the site of increase in EGP, liver versus kidney.
      Researchers will measure the rate of whole body glucose production with 3-3H-glucose (a form
      of radioactive glucose) and renal glucose production by renal vein catheterization in T2DM
      (type 2 diabetes mellitus) and in lean healthy NGT (normal glucose tolerance) individuals.
      Because the increase in EGP is associated with an increase in plasma glucagon concentration
      and renal glucose production is stated to be unresponsive to glucagon, the investigators
      anticipate that the liver will be responsible, in part, for the increase in EGP.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous Glucose Production NGT subjects - dapa</measure>
    <time_frame>3 weeks</time_frame>
    <description>Endogenous Glucose Production NGT subjects after dapagliflozin administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogenous Glucose Production NGT subjects - placebo</measure>
    <time_frame>3 weeks</time_frame>
    <description>Endogenous Glucose Production NGT subjects after placebo administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogenous Glucose Production T2DM subjects - dapa</measure>
    <time_frame>3 weeks</time_frame>
    <description>Endogenous Glucose Production T2DM subjects after dapagliflozin administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogenous Glucose Production T2DM subjects - placebo</measure>
    <time_frame>3 weeks</time_frame>
    <description>Endogenous Glucose Production T2DM subjects after placebo administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Glucose Production NGT subjects - dapa</measure>
    <time_frame>3 weeks</time_frame>
    <description>Renal Glucose Production NGT subjects after dapagliflozin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Glucose Production NGT subjects - placebo</measure>
    <time_frame>3 weeks</time_frame>
    <description>Renal Glucose Production NGT subjects after placebo administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Glucose Production T2DM subjects - dapa</measure>
    <time_frame>3 weeks</time_frame>
    <description>Renal Glucose Production T2DM subjects after dapagliflozin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Glucose Production T2DM subjects - placebo</measure>
    <time_frame>3 weeks</time_frame>
    <description>Renal Glucose Production T2DM subjects after placebo adminsitration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Normal Glucose Tolerance (NGT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with normal glucose tolerance - dapagliflozin vs placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with type 2 diabetes mellitus - dapagliflozin vs placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>dapagliflozin, 10mg tablet</description>
    <arm_group_label>Normal Glucose Tolerance (NGT)</arm_group_label>
    <arm_group_label>T2DM individuals</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for dapagliflozin</description>
    <arm_group_label>Normal Glucose Tolerance (NGT)</arm_group_label>
    <arm_group_label>T2DM individuals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25-35 kg/m^2

          -  Normal Glucose Tolerance subjects (24)

          -  Type 2 Diabetic Subjects (24)

          -  Diabetic subjects must be on a stable dose (more than 3 months) of monotherapy or
             combination therapy with metformin and/or a sulfonylurea

          -  Diabetic subjects must have HbA1c &lt;8.0%

          -  Other than diabetes, subjects must be in good general health as determined by physical
             exam, medical history, blood chemistries, CBC (complete blood count), TSH
             (thyroid-stimulating hormone), T4 (thyroxine), EKG (electrocardiogram) and
             urinanalysis.

          -  Only subjects whose body weight has been stable (Â± 3 lbs) over the preceding three
             months and who do not participate in an excessively heavy exercise program will be
             included.

        Exclusion Criteria:

          -  Subjects taking drugs known to affect glucose metabolism (other than metformin and
             sulfonylurea) will be excluded.

          -  Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine
             &gt;1.4 females or &gt;1.5 males, or 24-hour urine albumin excretion &gt; 300 mg will be
             excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugenio Cersosimo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugenio Cersosimo, MD, PhD</last_name>
    <phone>210-358-7200</phone>
    <email>cersosimo@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ralph DeFronzo, MD</last_name>
    <phone>210-567-6691</phone>
    <email>defronzo@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Eugenio Cersosimo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

